R.P. Scherer OTC softgel sales rise 10% to $29 mil. in first quarter.
This article was originally published in The Tan Sheet
SCHERER OTC SOFTGEL SALES RISE 10% IN FIRST QUARTER, to approximately $29 mil. worldwide for the period ended June 30. The increase resulted in part from higher sales of private label OTCs in a range of categories. Approximately one-third of OTC softgel sales are generated by the U.S. business. The soft gelatin capsule manufacturer reported a 7% gain in constant dollars of OTC and prescription pharmaceutical softgel sales combined for the quarter
You may also be interested in...
EU Regulatory Roundup, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.